Ovarian neoplasia and subfertility treatments

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 105, Issue 6, 1998, Pages 584-591

  Nugent, D ^a   Salha, O ^b   Balen, A H ^c   Rutherford, A J ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; DNA DETERMINATION; EPIDEMIOLOGICAL DATA; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY TUMOR; OVULATION INDUCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBFERTILITY; UNITED KINGDOM;

CASE-CONTROL STUDIES; FEMALE; HUMANS; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; OVULATION INDUCTION; RECEPTORS, GONADOTROPIN; RISK FACTORS;

EID: 0031798373     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1998.tb10171.x     Document Type: Review

References (97)

1. Heintz AP, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol 1985; 66: 127–135.
2. Office for National Statistics. Deaths Registered in 1995 by Cause, and by Area of Residence. London: Office for National Statistics, 1996 (ONS Monitor; DH2 96/2).
3. Speroff L, Glass RH, Kase NG. Induction of ovulation. In: Speroff L, Glass RH, Kase NG, editors. Clinical Gynaecologic Endocrinology and Infirtility. Baltimore: Williams & Wilkins, 1989: 583–609.
4. Jones HWJr, Jones GS, Andrews MC et al. The program for in vitro fertilisation at Norfolk. Fertil Steril 1982; 38: 14–21.
5. Chappel S, Kelton C, Nugent N. Expression of human gonadotrophins by recombinant DNA methods. In: Genazzi AR, Petraglia F, editors. Proceedings of the Third World Congress on Gynecological Endocrinology. Carnforth: Parthenon Publishing Group, 1992: 179–184.
6. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. Cancer J Clinic 1994; 44: 7–26.
7. Cramer DW, Cutler SJ. Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol 1974; 118: 443–460.
8. DiSaia PJ. Ovarian disorders. In Scott JR, DiSaia PJ, Hammond CB, Spellacy WN, editors. Darnforth's Obstetrics and Gynaecology. Philadelphia: JB Lippincott Co, 1990: 1067–1120.
9. Surveillance, Epidemiology, End Results 1973–1990. National Cancer Institute, Bethesda, Maryland, 1990.
10. Weiss N, Homonchuck T, Young J. Incidence of the histologic types of ovarian cancer: The US Third National Cancer Survey, 1966–1971. Gynecol Oncol 1977; 5: 161–167.
11. Piver MS, Mettlin CJ, Tsukada Y et al. Familial ovarian cancer registry. Obstet Gynecol 1984; 64: 195–199.
12. Lynch HT, Schuelke GS, Well IC et al. Hereditary ovarian carcinoma: biomarker study. Cancer 1985; 55: 410–415.
13. Lynch HT, Bewtra C, Lynch JF. Familial ovarian carcinoma: clinical nuances. Am Med J 1986; 81: 1073–1076.
14. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res 1967; 1: 115–128.
15. Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer study. Cancer 1982; 50: 372–376.
16. Stadel BV. The aetiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975; 123: 772–774.
17. Newhouse ML, Pearson RM, Fullerton JM et al. A case study of carcinoma of the ovary. Br J Prev Soc Med 1977; 31: 148–153.
18. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR. Case-control study of borderline tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48: 5489–5852.
19. Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 9–23.
20. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experience and family history. J Natl Cancer Inst 1983; 71: 711–716.
21. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 1982; 115: 714–719.
22. Franceschi S. Reproductive factors and cancers of the breast, ovary and endometrium. Eur J Cancer Clin Oncol 1989; 25: 1933–1943.
23. Nasca PC, Greenwald P, Chorost S, Richert R, Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984; 119: 705–713.
24. Whittemore AS, Harris R, Itnyre J. The Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184–1203.
25. Joly DJ, Lilienfield AM, Diamond EL, Bross IDJ. An epjdemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 1974; 99: 190–209.
26. McGowan L, Parent L, Lednar W, Noms HJ. The women at risk of developing ovarian cancer. Gynecol Oncol 1979; 7: 325–344.
27. Heintz A, Hacker N, Lagasse L. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol 1985; 66: 127–135.
28. Wu ML, Whittemore AS, Paffenbarger RS et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol 1988; 128: 1216–1227.
29. Hankinson SE, Golditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80: 708–714.
30. Harris R, Whittemore AS, Itnyre J. The Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk collaborative analysis of 12 US casecontrol studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992; 136: 1204–1211.
31. Scott JS. How to induce ovarian cancer and how not to. BMJ 1984; 289: 781–782.
32. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia Lancet 1971; 2: 163.
33. Zajicek J. Prevention of ovarian cystomas by inhibition of ovulation: a new concept. J Reprod Med 1978; 2: 114.
34. Casagrande JT, Pike ML, Ross RK, Louis EW, Roy S, Henderson BE. Incessant ovulation and ovarian cancer. Lancet 1979; 2: 170–172.
35. Gardner WU. Tumorogenesis in transplanted irradiated and nonirradiated ovaries. J Nat Cancer Inst 1961; 26: 829–853.
36. Henderson BF, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988; 48: 246–253.
37. Atkin NB, Baker MC. Abnormal chromosomes including small metacentrics in 14 ovarian cancers. Cancer Genet Gytogenr 1987; 26: 355–361.
38. McGowan L, Davis RH. Intrasplenic ovarian grafts in Syrian hamsters and peritoneal fluid cellular distribution. Proc Soc Exp Biol Med 1970; 134: 507–509.
39. Shirama K, Hokano M. Ultrastructural study on experimentally induced ovarian tumors in the rat. J Endocrinol Invest 1992; 15: 417–422.
40. Rajaniemi H, Kauppila A, Ronnberg L, Selander K, Pystynen P. LH (hCG) receptor in benign and malignant tumors of the ovary. Acta Obstet Gynecol Scand 1981; 101: 83–86.
41. Kammerman S, Demopoulos RI, Raphael C, Ross J. Gonadotrophic hormone binding to human ovarian tumors. Hum Path 1981; 12: 886–890.
42. Stouffer RL, Grodin MS, Davis JR, Surwit EA. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotrophin in human ovarian cancers. J Clin Endocrinol 1984; Metab 59: 441–446.
43. Simon WE, Holzel F. Hormone sensitivity of gynecological tumor cells in tissue cultures. J Cancer Res Clin Oncol 1979; 94: 307–323.
44. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F. Cell lines derived from human ovarian carcinomas; growth stimulation by gonadotrophic and steroid hormones. J Natl Cancer Inst 1983; 70: 839–845.
45. Richman CM, Holt JA, Lorincz MA, Herbst AL. Persistence and distribution of estrogen receptor in advanced epithelial ovarian carcinoma after chemotherapy. Obstet Gynecol 1985; 65: 257–263.
46. Bizzi A, Codegani AM, Landoni F et al. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Res. 1988; 48: 6222–6226.
47. Nash JP, Ozols RF, Smyth JF et al. Estrogen and anti-oestrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989; 73: 1009–1016.
48. Vierikko P, Kauppilla A, Vihko R. Cytosol and nuclear estrogen and progesterone receptors and 17β-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumours of the human ovary. Int J Cancer 1983; 32: 413–422.
49. Cramer DW, Welch WR. Determinants of ovarian cancer risk II: Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717–721.
50. Bengtsson M, Rydstrom J. Regulation of carcinogen metabolism in the rat ovary by the oestrous cycle and gonadotrophin. Science 1983; 219: 1437–1438.
51. Bengtsson M, Hamberger L, Rydstrom J. Metabolism of 7,12-dimethylbenzene(a)anthracene by different cell types in the human ovary. Xenobiotica 1988; 18: 1255–1270.
52. Balen AH, Braat DDM, West C, Patel A, Jacobs HS. Cumulative conception and live birth rates after the treatment of anovulatory infertility. An analysis of the safety and efficacy of ovulation induction in 200 patients. Hum Reprod 1994; 9: 1563–1570.
53. Balen AH. The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Hum Reprod 1995; 10: 2233–2237.
54. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 592–598.
55. Whittemore AS, Wu ML, Paffenbarger RS et al. Epithelial ovarian cancer and ability to conceive. Cancer Res. 1989; 49: 4047–4052.
56. Risch HA, Marrett LD, Hove GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 585–597.
57. Venn A, Watson L, Lumley J et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346: 995–1000.
58. Bamford PM, Steele SJ. Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy a case report. Br J Obstet Gynaecol 1982; 89: 962–964.
59. Kaufman SC, Spirtas R, Alexander NJ. Do fertility drugs cause ovarian tumors J Women Health 1995; 4: 247–259.
60. Balen AH, Jacobs HS. Infertility in Practice. London: Churchill Livingstone, 1997: 155–160.
61. Huppert LC. Induction of ovulation with clomiphene citrate. Fertil Steril 1979; 31: 1–8.
62. Nikrui N. Survey of clinical behaviour of patients with borderline epithelial tumours of the ovary. Gynecol Oncol 1985; 12: 107–119.
63. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971; 37: 1–9.
64. Julian CG, Woodruff JD. The biologic behaviour of low grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40: 860–867.
65. Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumours. J Natl Cancer Inst 1987; 78: 71–74.
66. Scully RE. Common epithelial tumors of borderline malignancy (carcinoma of low malignant potential). Bull Cancer (Paris) 1982; 69: 228–238.
67. Colgan TJ, Horris HJ. Ovarian epithelial tumors of low malignant potential: a review. Int J Gynecol Pathol 1983; 1: 376–382.
68. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation Is there a link Am J Obstet Gynecol 1992; 166: 853–854.
69. Ron E, Lunenfield B, Menczer J et al. Cancer incidence in a cohort of infertile women. Am J Epidimiol 1987; 125: 780–790.
70. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based casecontrol study of ovarian cancer in Shanghai. Cancer Res 1989; 49: 3670–3674.
71. Whittemore AS, Harris R, Itnyre J, Halpern J. The Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US casecontrol studies. I. Methods. Am J Epidemiol 1992; 136: 1175–1183.
72. Cohen J, Forman R, Harlap S et al. Fertility drugs and ovarian cancer. Fertil Steril. 1993; 60: 406–408.
73. Spirats R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring Fertil Steril 1993; 59: 291–293.
74. Darder MC. Fertility drugs and ovarian cancer: red alert or red herring new information [letter]. Fertil Steril 1993; 60: 199.
75. Whittemore AS. The risk of ovarian cancer after treatment for infertility. N Engl J Med 1994; 331: 805–806.
76. Rossing MA, Darling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771–776.
77. Shushan A, Paltiel O, Iscovich J et al. Human menopausal gonadotrophin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65: 13–18.
78. Marrs RP, Hark SC. Comments on the possible association between ovulation induction agents and ovarian cancer. The American Fertility Society, Birmingham, Alabama, January 1993.
79. Lund E. Mortality from ovarian cancer among women with many children. Int J Epidemiol 1992; 21: 872–876.
80. Negri E, Franceschi S, Tzonou A et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of ovarian epithelial ovarian cancer. Int J Cancer 1991; 49: 50–56.
81. International Federation of Fertility Societies. Fertility drugs and ovarian cancer. Fertil Steril 1993; 60: 406–408.
82. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11: 917–919.
83. Levene MI, Wild J, Steer P. Higher multiple births and the modem management of infertility in Britain. Br J Obsret Gynaecol 1992; 99: 607–613.
84. Botting BJ, MacFarlane AJ, Price FV. Three, four and more. A study of triplet and higher order births. London: HMSO, 1990.
85. Balen AH, MacDougall J, Tan SL. The influence of the number of embryos transferred during in-vitro fertilization on pregnancy outcome. Hum Reprod 1993; 8: 1324–1328.
86. Polson DW, Mason HD, Saldanha BY, Franks S. Ovulation of a single dominant follicle during treatment with low dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin Endocrinol 1987; 26: 205–212.
87. Hamilton-Fairley D, Kiddy DS, Watson H, Sagle M, Franks S. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991; 6: 1095–1099.
88. Shoham Z, Patel A, Jacobs HS. Polycystic ovary syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55: 1051–1056.
89. Armar NA, McGarrigle HHG, Honour JW, Holownia P, Jacobs HS, Lachelin GCL. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 1990; 53: 45–49.
90. Armar NA, Lachelin GCL. Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with polycystic ovaries. Br J Obstet Gynaecol 1993; 100: 161–164.
91. Donesky BW, Adashi EY. Surgically induced ovulation in the PCOS: wedge resection revisited in the age of laparoscopy. Fertil Steril 1995; 63: 439–463.
92. Balen AH, Jacobs HS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994; 62: 921–925.
93. Gosden RG, Wynn P, Krapez J, Rutherford AJ, Sharma V. In vitro maturation of oocytes. RCOG 1997 Yearbook, Carnforth: Parthenon Publishing Group, 1997.
94. Trounson AO, Bongso A, Szell A, Barnes FL. Maturation of human and bovine primary oocytes in in vitro for fertilisation and embryo production. Singapore J Obstet Gynecol 1996; 27: 78–84.
95. Cha KY. In-vitro maturation of follicles and oocytes: oocytes from unstimulated follicles [abstract]. Human Oocytes: From Physiology to IVF. University of Bologna, Italy, 2123 April, 1997.
96. Oktay K, Newton H, Aubard Y, Salha O, Gosden RG. Cryopreservation of immature human oocytes and ovarian tissue: an emerging technology Fertil Steril 1998; 69: 1–7.
97. Eppig JJ, O'Brien MJ. Development in vitro of mouse oocytes from primordial follicles. Biol Reprod 1996; 54: 197–207.